CM Life Sciences, Inc. Profile Avatar - Palmy Investing

CM Life Sciences, Inc.

CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.

Shell Companies
US, New York [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 56% Somewhat Positive
Profitability n.A. n.A.
Fin. Growth 17% Weak
Leverage & Liquidity 17% Weak
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q2 Δ in %
EV/EBITDA -98.12 59.59 -3172.54
Graham Fair Price 722.64 0.69 0.08
PEG 100.00 < 0.005 0.00
Price/Book 26.90 155.07 122.20
Price/Cash Flow 97.22 -836.68 -30101.27
Prices/Earnings -98.12 14.90 -794.56
Price/Sales 0.00 0.00 0.00
Price/FCF 97.22 -836.68 -30101.27
Naive Interpretation member
01 - Valuation · Somewhat Positive
Fundamentals

Profitability

Metric Q4 Q2 Δ in %
Gross Profit Margin 0.00 0.00 0.00
Operating Margin 0.00 0.00 0.00
ROA 6681.94 0.03 < 0.005
ROE -0.04 2.60 6667.38
ROIC < 0.005 < 0.005 -518.52
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q2 Δ in %
Debt QOQ 0.00 0.00 0.00
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.00 -5.20 -100.00
EPS QOQ 0.00 81.00 100.00
FCF QOQ 0.00 -44.66 -100.00
Revenue QOQ 0.00 0.00 0.00
Naive Interpretation member
03 - Financial Growth · Weak
Fundamentals

Leverage & Liquidity

Metric Q4 Q2 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 0.00 0.00 0.00
Days Sales Outstanding (DSO) 0.00 0.00 0.00
Inventory Turnover 0.00 0.00 0.00
Debt/Capitalization 0.00 0.00 0.00
Quick Ratio 4570.21 197.31 -95.68
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q2 Δ in %
Book Value 0.09 0.09 < 0.005
Cash 8.02 8.00 -0.20
Capex 0.00 0.00 0.00
Free Cash Flow < 0.005 -0.02 -4465.58
Revenue 0.00 0.00 0.00
Naive Interpretation member
05 - Per Share Metrics · Bad
Fundamentals

Financial Health

Metric Q4 Q2 Δ in %
Current Ratio 14.12 0.18 -98.75
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 5.69 -0.01 -99.77
Naive Interpretation Member
06 - Financial Health · Bad
End of CMLFU's Analysis
CIK: 1818331 CUSIP: - ISIN: US18978W2089 LEI: - UEI: -
Secondary Listings
CMLFU has no secondary listings inside our databases.